Pathogen Inactivation Plays an Irreplaceable Role in Safeguarding the Safety of Blood Transfusion

Yao, Ming

doi:10.4172/jaa.1000e133

Cited by 2 publications

(2 citation statements)

References 13 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a direct consequence, we may need to rely increasingly on PI technology in the future. [3] For plasma and platelets, various costly PI techniques are available: Solvent/Detergent techniques and photochemical inactivation techniques, using methylene blue, amotosalen/UVA or ribo avin/UVB. [2] All with its own limitations like the damaging of platelets (and RBCs) by UV light [2] and risk of contamination caused by handling of RBC concentrates.…”

Section: Introductionmentioning

confidence: 99%

Type of the Paper: Article Homogenous Gamma-Irradiation by a Linear Accelerator for Inactivation of viruses in Plasma Samples, a Pilot Study with HIV-1-Infected Plasma

Tonino¹,

Franken²,

Elzakker³

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUNDThe risk of the transmission of (emerging) infectious diseases via blood products is a major public health concern. Therefore, it has been a long-sought goal to find a cost-effective way to sterilise blood after collection. No pathogen inactivation (PI) techniques are available for red blood cells on the market yet, though phase III trials are currently performed. γ-irradiation could theoretically inactivate viruses in red blood cells (RBCs). The dose of γ-irradiation needed to achieve sterility causes irreversible damage to the red blood cells and is therefore not suitable for PI of RBC concentrates. Inhomogeneous irradiation has always been used in the past, but leads to inconsistent measurements and uncertainty of results. By contrast, homogeneous irradiation may achieve the sterility assurance level (SAL) at much lower doses. If a maximum of 25 Gy of homogeneous γ-irradiation is able to sterilise blood products, this would be a very attractive PI method for RBC products. METHODSThis proof-of-concept study aims to sterilise HIV-1 infected plasma using homogeneous γ-irradiation. Six HIV-1 infected plasma samples were irradiated with 25 Gy of homogeneous γ-irradiation. HIV-1 RNA-loads before and after were compared.RESULTSNo difference was found in the HIV-1 RNA loads within the limitations of the test used before and after the irradiation. Therefore, homogeneous γ-irradiation appears not to be feasible as a PI-technique for HIV-1 in RBC products. CONCLUSIONThis inevitably means SAL will not be achieved for all viruses with up to 25 Gy of homogeneous γ-irradiation.

show abstract

Section: Introductionmentioning

confidence: 99%

Type of the Paper: Article Homogenous Gamma-Irradiation by a Linear Accelerator for Inactivation of viruses in Plasma Samples, a Pilot Study with HIV-1-Infected Plasma

Tonino¹,

Franken²,

Elzakker³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The incubation time was depending from virus type, R/D concentration and detergent nature and can continue from 2-5 min [9] to 6-24 hrs [9,10] to achieve a satisfied virus reduction. Normally the temperature of the treatment process was limited by the fast FVIII denaturation and did not exceed 30 [2][3][4][5], less often 2-8 [1,3,10] or 37˚C [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

The Simultaneous Human FVIII/vWF Purification and Virus Inactivation Combined in Chromatographic Column

Volkov¹

2017

J Biomol Res Ther

View full text Add to dashboard Cite

Pathogen Inactivation Plays an Irreplaceable Role in Safeguarding the Safety of Blood Transfusion

Cited by 2 publications

References 13 publications

Type of the Paper: Article Homogenous Gamma-Irradiation by a Linear Accelerator for Inactivation of viruses in Plasma Samples, a Pilot Study with HIV-1-Infected Plasma

Type of the Paper: Article Homogenous Gamma-Irradiation by a Linear Accelerator for Inactivation of viruses in Plasma Samples, a Pilot Study with HIV-1-Infected Plasma

The Simultaneous Human FVIII/vWF Purification and Virus Inactivation Combined in Chromatographic Column

Contact Info

Product

Resources

About